Strategic moves drive net sales over €9B in dsm-firmenich FY 2025
Key takeaways
- dsm-firmenich achieved net sales of over €9 billion, with 3% organic growth, aided by strategic divestments.
- The Health, Nutrition & Care division grew with innovations in Early Life Nutrition and HMOs.
- The Taste, Texture & Health division saw 4% growth, driven by China and India.
In its newly released annual financial report for 2025, dsm-firmenich attributes its financial performance to strategic moves, share repurchases, and divestments. For continued operations, the company reports overall net sales of €9.03 billion (US$10.7 billion) and a 3% volume-led organic sales growth.
The health ingredients supplier comments that performance was “solid” despite the challenging macroeconomic environment over the past year.
For Health, Nutrition and Care (HNC), net sales amounted to €2.1 billion (US$2.49 billion) and adjusted earnings before interest, taxes, depreciation, and amortisation (EBITDA) were €407 million (US$482 million).
The company reports changes in HNC, including the Animal Nutrition & Health divestment that was finalized earlier this week. The company sold the business to private equity firm CVC Capital Partners for approximately €2.2 billion (~US$2.6 billion).
Taking total group discontinued operations into account, there was a 10% increase in net sales compared to FY 2024, and net sales of €12.5 billion (US$14.8 billion).
Early life to healthy aging
The HNC division increased by 3% organic sales growth, supported by Dietary Supplements and Early Life Nutrition. HNC growth softened somewhat in the second half due to “more cautious consumer sentiment in North America.”
The HNC division increased by 3% organic sales growth.The company details: “During the year, HNC delivered innovations reflecting its commitment to shaping the future of health — from early life to healthy aging — through science‑driven, sustainable nutrition solutions that improve lives at every stage.”
It exemplifies strengthening its Early Life Nutrition franchise with regulatory approvals for human milk oligosaccharides (HMOs) in over 170 countries. Notably, in China, with its Glycare HMO portfolio.
In microbiome health, the report notes the clinically proven postbiotic Humione, available in an allergen-free form, making it suitable for use in various formats, such as gummies.
It also advanced in sustainable nutrition by expanding its algal lipid portfolio with life’s Omega 02722 in China. The ingredient is a single-source algal omega-3 with the same ratio of eicosapentaenoic and docosahexaenoic acids, but twice the potency of standard fish oil.
China and India driving growth
For the Taste, Texture & Health (TTH) division, sales were reported at €3.146 billion (US$3.73 billion) and organic sales growth of 4%.
China and India were the main growth drivers throughout the full year for the TTH division.“TTH delivered an organic sales growth of 4%, supported by sales synergies, against a high prior year comparable of 10%, and more cautious customer demand in the second half of the year. Local & Regional customers generated stronger growth compared to global customers,” details the report.
Geographically, China and India were the main growth drivers throughout the full year. Europe performed well, although it softened in the second half. North America, Asia-Pacific, and Latin America remained “comparatively weaker,” the company notes.
In October last year, the company opened its Van Marken Food Innovation Center in Delft, the Netherlands — the headquarters of the company’s more than €3 billion (US$3.53 billion) TTH business unit. It is designed to help its customers develop more nutritious and sustainable F&B solutions.
The report also details the company’s goal to reduce the micronutrient gap through nutritional interventions and innovations. In 2025, dsm-firmenich details that its products reached 775 million people, a slight increase from 2024’s 759 million.
